Skip to main content
Clinical Trials/RPCEC00000335
RPCEC00000335Recruiting未知

Safety and effectiveness of BIOMODULINA T in a long-lived population at high risk of COVID-19 infection. Interventional Study (COVID-19)

Centro Nacional de Biopreparados (BioCen)0 sitesStarted: September 19, 2020Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention

Eligibility Criteria

Ages
75 years to one (—)
Sex
All

Inclusion Criteria

  • 1. Age 75 years and over.
  • 2. Any sex and skin color.
  • 3. Patients who express their consent in writing, to participate in the study and in the event that major cognitive impairment is present, be signed by a family member, tutor or caregiver.

Exclusion Criteria

  • 1. Patients who have received treatment with BIOMODULINA T® in the previous two months.
  • 2. Patients with known hypersensitivity to any component of the formulation.
  • 3. Patients with acute allergic states or history of severe allergic reactions.
  • 4. Patients with uncontrolled intercurrent illnesses including, but not limited to: acute infections with concomitant febrile symptoms, symptomatic congestive heart failure, unstable angina pectoris.

Investigators

Sponsor
Centro Nacional de Biopreparados (BioCen)

Similar Trials